Cargando…
Persistent morbidity in Clade IIb mpox patients: interim results of a long-term follow-up study, Belgium, June to November 2022
While mpox was well characterised during the 2022 global Clade IIb outbreak, little is known about persistent morbidity. We present interim results of a prospective cohort study of 95 mpox patients assessed 3–20 weeks post-symptom onset. Two-thirds of participants had residual morbidity, including 2...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Centre for Disease Prevention and Control (ECDC)
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936596/ https://www.ncbi.nlm.nih.gov/pubmed/36795501 http://dx.doi.org/10.2807/1560-7917.ES.2023.28.7.2300072 |
| _version_ | 1784890264181014528 |
|---|---|
| author | Berens-Riha, Nicole Bracke, Stefanie Rutgers, Jojanneke Burm, Christophe Van Gestel, Liesbeth Hens, Matilde Kenyon, Chris Bottieau, Emmanuel Soentjens, Patrick Brosius, Isabel Van Esbroeck, Marjan Vercauteren, Koen van Griensven, Johan van Dijck, Christophe Liesenborghs, Laurens De Baetselier, Irith Van den Bossche, Dorien Ariën, Kevin K Coppens, Jasmine Vanroye, Fien Ramadan, Kadrie Van Looveren, Karin Baeyens, Jolien Heyndrickx, Leo Rasson, Hanne Verschueren, Jacob Rezende, Antonio Vandenhove, Leen Vuylsteke, Bea |
| author_facet | Berens-Riha, Nicole Bracke, Stefanie Rutgers, Jojanneke Burm, Christophe Van Gestel, Liesbeth Hens, Matilde Kenyon, Chris Bottieau, Emmanuel Soentjens, Patrick Brosius, Isabel Van Esbroeck, Marjan Vercauteren, Koen van Griensven, Johan van Dijck, Christophe Liesenborghs, Laurens De Baetselier, Irith Van den Bossche, Dorien Ariën, Kevin K Coppens, Jasmine Vanroye, Fien Ramadan, Kadrie Van Looveren, Karin Baeyens, Jolien Heyndrickx, Leo Rasson, Hanne Verschueren, Jacob Rezende, Antonio Vandenhove, Leen Vuylsteke, Bea |
| author_sort | Berens-Riha, Nicole |
| collection | PubMed |
| description | While mpox was well characterised during the 2022 global Clade IIb outbreak, little is known about persistent morbidity. We present interim results of a prospective cohort study of 95 mpox patients assessed 3–20 weeks post-symptom onset. Two-thirds of participants had residual morbidity, including 25 with persistent anorectal and 18 with genital symptoms. Loss of physical fitness, new-onset/worsened fatigue and mental health problems were reported in 36, 19 and 11 patients, respectively. These findings require attention by healthcare providers. |
| format | Online Article Text |
| id | pubmed-9936596 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | European Centre for Disease Prevention and Control (ECDC) |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-99365962023-02-18 Persistent morbidity in Clade IIb mpox patients: interim results of a long-term follow-up study, Belgium, June to November 2022 Berens-Riha, Nicole Bracke, Stefanie Rutgers, Jojanneke Burm, Christophe Van Gestel, Liesbeth Hens, Matilde Kenyon, Chris Bottieau, Emmanuel Soentjens, Patrick Brosius, Isabel Van Esbroeck, Marjan Vercauteren, Koen van Griensven, Johan van Dijck, Christophe Liesenborghs, Laurens De Baetselier, Irith Van den Bossche, Dorien Ariën, Kevin K Coppens, Jasmine Vanroye, Fien Ramadan, Kadrie Van Looveren, Karin Baeyens, Jolien Heyndrickx, Leo Rasson, Hanne Verschueren, Jacob Rezende, Antonio Vandenhove, Leen Vuylsteke, Bea Euro Surveill Rapid Communication While mpox was well characterised during the 2022 global Clade IIb outbreak, little is known about persistent morbidity. We present interim results of a prospective cohort study of 95 mpox patients assessed 3–20 weeks post-symptom onset. Two-thirds of participants had residual morbidity, including 25 with persistent anorectal and 18 with genital symptoms. Loss of physical fitness, new-onset/worsened fatigue and mental health problems were reported in 36, 19 and 11 patients, respectively. These findings require attention by healthcare providers. European Centre for Disease Prevention and Control (ECDC) 2023-02-16 /pmc/articles/PMC9936596/ /pubmed/36795501 http://dx.doi.org/10.2807/1560-7917.ES.2023.28.7.2300072 Text en This article is copyright of the authors or their affiliated institutions, 2023. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made. |
| spellingShingle | Rapid Communication Berens-Riha, Nicole Bracke, Stefanie Rutgers, Jojanneke Burm, Christophe Van Gestel, Liesbeth Hens, Matilde Kenyon, Chris Bottieau, Emmanuel Soentjens, Patrick Brosius, Isabel Van Esbroeck, Marjan Vercauteren, Koen van Griensven, Johan van Dijck, Christophe Liesenborghs, Laurens De Baetselier, Irith Van den Bossche, Dorien Ariën, Kevin K Coppens, Jasmine Vanroye, Fien Ramadan, Kadrie Van Looveren, Karin Baeyens, Jolien Heyndrickx, Leo Rasson, Hanne Verschueren, Jacob Rezende, Antonio Vandenhove, Leen Vuylsteke, Bea Persistent morbidity in Clade IIb mpox patients: interim results of a long-term follow-up study, Belgium, June to November 2022 |
| title | Persistent morbidity in Clade IIb mpox patients: interim results of a long-term follow-up study, Belgium, June to November 2022 |
| title_full | Persistent morbidity in Clade IIb mpox patients: interim results of a long-term follow-up study, Belgium, June to November 2022 |
| title_fullStr | Persistent morbidity in Clade IIb mpox patients: interim results of a long-term follow-up study, Belgium, June to November 2022 |
| title_full_unstemmed | Persistent morbidity in Clade IIb mpox patients: interim results of a long-term follow-up study, Belgium, June to November 2022 |
| title_short | Persistent morbidity in Clade IIb mpox patients: interim results of a long-term follow-up study, Belgium, June to November 2022 |
| title_sort | persistent morbidity in clade iib mpox patients: interim results of a long-term follow-up study, belgium, june to november 2022 |
| topic | Rapid Communication |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936596/ https://www.ncbi.nlm.nih.gov/pubmed/36795501 http://dx.doi.org/10.2807/1560-7917.ES.2023.28.7.2300072 |
| work_keys_str_mv | AT berensrihanicole persistentmorbidityincladeiibmpoxpatientsinterimresultsofalongtermfollowupstudybelgiumjunetonovember2022 AT brackestefanie persistentmorbidityincladeiibmpoxpatientsinterimresultsofalongtermfollowupstudybelgiumjunetonovember2022 AT rutgersjojanneke persistentmorbidityincladeiibmpoxpatientsinterimresultsofalongtermfollowupstudybelgiumjunetonovember2022 AT burmchristophe persistentmorbidityincladeiibmpoxpatientsinterimresultsofalongtermfollowupstudybelgiumjunetonovember2022 AT vangestelliesbeth persistentmorbidityincladeiibmpoxpatientsinterimresultsofalongtermfollowupstudybelgiumjunetonovember2022 AT hensmatilde persistentmorbidityincladeiibmpoxpatientsinterimresultsofalongtermfollowupstudybelgiumjunetonovember2022 AT kenyonchris persistentmorbidityincladeiibmpoxpatientsinterimresultsofalongtermfollowupstudybelgiumjunetonovember2022 AT bottieauemmanuel persistentmorbidityincladeiibmpoxpatientsinterimresultsofalongtermfollowupstudybelgiumjunetonovember2022 AT soentjenspatrick persistentmorbidityincladeiibmpoxpatientsinterimresultsofalongtermfollowupstudybelgiumjunetonovember2022 AT brosiusisabel persistentmorbidityincladeiibmpoxpatientsinterimresultsofalongtermfollowupstudybelgiumjunetonovember2022 AT vanesbroeckmarjan persistentmorbidityincladeiibmpoxpatientsinterimresultsofalongtermfollowupstudybelgiumjunetonovember2022 AT vercauterenkoen persistentmorbidityincladeiibmpoxpatientsinterimresultsofalongtermfollowupstudybelgiumjunetonovember2022 AT vangriensvenjohan persistentmorbidityincladeiibmpoxpatientsinterimresultsofalongtermfollowupstudybelgiumjunetonovember2022 AT vandijckchristophe persistentmorbidityincladeiibmpoxpatientsinterimresultsofalongtermfollowupstudybelgiumjunetonovember2022 AT liesenborghslaurens persistentmorbidityincladeiibmpoxpatientsinterimresultsofalongtermfollowupstudybelgiumjunetonovember2022 AT persistentmorbidityincladeiibmpoxpatientsinterimresultsofalongtermfollowupstudybelgiumjunetonovember2022 AT persistentmorbidityincladeiibmpoxpatientsinterimresultsofalongtermfollowupstudybelgiumjunetonovember2022 AT debaetselieririth persistentmorbidityincladeiibmpoxpatientsinterimresultsofalongtermfollowupstudybelgiumjunetonovember2022 AT vandenbosschedorien persistentmorbidityincladeiibmpoxpatientsinterimresultsofalongtermfollowupstudybelgiumjunetonovember2022 AT arienkevink persistentmorbidityincladeiibmpoxpatientsinterimresultsofalongtermfollowupstudybelgiumjunetonovember2022 AT coppensjasmine persistentmorbidityincladeiibmpoxpatientsinterimresultsofalongtermfollowupstudybelgiumjunetonovember2022 AT vanroyefien persistentmorbidityincladeiibmpoxpatientsinterimresultsofalongtermfollowupstudybelgiumjunetonovember2022 AT ramadankadrie persistentmorbidityincladeiibmpoxpatientsinterimresultsofalongtermfollowupstudybelgiumjunetonovember2022 AT vanlooverenkarin persistentmorbidityincladeiibmpoxpatientsinterimresultsofalongtermfollowupstudybelgiumjunetonovember2022 AT baeyensjolien persistentmorbidityincladeiibmpoxpatientsinterimresultsofalongtermfollowupstudybelgiumjunetonovember2022 AT heyndrickxleo persistentmorbidityincladeiibmpoxpatientsinterimresultsofalongtermfollowupstudybelgiumjunetonovember2022 AT rassonhanne persistentmorbidityincladeiibmpoxpatientsinterimresultsofalongtermfollowupstudybelgiumjunetonovember2022 AT verschuerenjacob persistentmorbidityincladeiibmpoxpatientsinterimresultsofalongtermfollowupstudybelgiumjunetonovember2022 AT rezendeantonio persistentmorbidityincladeiibmpoxpatientsinterimresultsofalongtermfollowupstudybelgiumjunetonovember2022 AT vandenhoveleen persistentmorbidityincladeiibmpoxpatientsinterimresultsofalongtermfollowupstudybelgiumjunetonovember2022 AT vuylstekebea persistentmorbidityincladeiibmpoxpatientsinterimresultsofalongtermfollowupstudybelgiumjunetonovember2022 |